SCHEDULE: Jorey Chernett Discloses 6.8% Stake in Traws Pharma

Jorey Chernett has reported a 6.8% beneficial ownership stake in Traws Pharma, Inc., holding 543,268 common shares as a passive investor.

Summary

• Jorey Chernett has filed a Schedule 13G, disclosing beneficial ownership of 543,268 common shares of Traws Pharma, Inc.
• This ownership represents 6.8% of Traws Pharma, Inc.'s common stock.
• The filing indicates that the shares were acquired for investment purposes and not with the intent to change or influence control of the issuer.
• Chernett holds sole voting power and sole dispositive power over all 543,268 shares.
• The event requiring this filing occurred on January 14, 2026.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, which is neutral in sentiment. The certification of passive intent mitigates potential negative interpretations of a large stake, while the existence of a new significant shareholder could be seen as mildly positive.

Positives

• The disclosure of a new significant individual shareholder, Jorey Chernett, holding 6.8% of common stock, could be viewed as a vote of confidence in Traws Pharma, Inc.

Risks

• The reporting person certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11, which could imply a potential for future proxy contest related to board nominations.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Traws Pharma, Inc.'s future performance or operations.

Management Comments

• Jorey Chernett certified that, to the best of their knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Traws Pharma, Inc., and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This filing is a disclosure of beneficial ownership and does not provide specific industry context or analysis related to Traws Pharma, Inc.'s operations or broader industry trends.

Stakeholder Impact

• Shareholders: The disclosure of a new significant shareholder holding 6.8% of the common stock provides transparency regarding the company's ownership structure. While the intent is passive, the potential for a nomination under Rule 240.14a-11 could be of interest to shareholders regarding future board composition.

Key Dates

Keywords

Traws Pharma, Jorey Chernett, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, SEC Filing, Shareholder Stake